Association Between Mitochondrial DNA Content and Risk of Acute Leukemia

Lymphoblastic Leukemia in Children Clinical Trial

Official title:
Association Between Mitochondrial DNA Content and Risk of Acute Leukemia in Young Adult

Status Completed

Clinical Trial Summary

Compelling epidemiological evidence indicates that alterations of mitochondrial DNA, including mutations and abnormal content of mitochondrial DNA (mtDNA), are associated with the initiation and development of acute lymphoblastic leukemia (ALL).The aim of this study was to explore association between mtDNA content in peripheral blood cells could be used as a risk predictor for ALL.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Leukemia
Lymphoblastic Leukemia in Children

Clinical Trial Details

NCT number	NCT03595969
Study type	Observational
Source	Fourth Military Medical University
Contact
Status	Completed
Phase
Start date	November 1, 2018
Completion date	October 1, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05043571` - CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia	Phase 1
Recruiting	`NCT06099366` - Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children	Phase 2
Recruiting	`NCT05648019` - CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol	Phase 2
Recruiting	`NCT05429905` - Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia	Phase 1/Phase 2
Recruiting	`NCT05038696` - ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.	Phase 1